Journal Information
Vol. 46. Issue 7.
Pages 364-369 (July 2010)
Share
Share
Download PDF
More article options
Vol. 46. Issue 7.
Pages 364-369 (July 2010)
Original Article
Full text access
Pre-treatment and treatment-Induced Neuron-specific Enolase in Patients with Small-Cell Lung Cancer: An Open Prospective Study
Valores pretratamiento e inducidos por el tratamiento de enolasa específica de neurona en pacientes con cáncer de pulmón microcítico: estudio prospectivo, abierto
Visits
5061
Ahmet Emin Erbaycua,
Corresponding author
drerbaycu@yahoo.com

Corresponding author.
, Ayriz Gunduzb, Ozgur Batuma, Zeynep Zeren Ucara, Fevziye Tuksavula, Salih Zeki Guclua
a Department of Thoracic Diseases, Izmir Dr Suat Seren Thoracic Diseases and Surgery Training and Research Hospital, Izmir, Turkey
b Department of Microbiology, Izmir Dr Suat Seren Thoracic Diseases and Surgery Training and Research Hospital, Izmir, Turkey
This item has received
Article information
Abstract
Background

Neuron-specific enolase (NSE) is the most sensitive tumour marker for small-cell lung carcinoma (SCLC) at the time of diagnosis. The main purpose of this study was to review the usefulness of serum NSE level as a prognostic factor in patients with SCLC and to determine the correlation between the NSE level and the stage of disease and response to chemotherapy.

Methods

In this prospective study, patients with SCLC were evaluated for response to chemotherapy, survival without disease progression, and overall survival. The end point was designated at patient death due to SCLC. NSE assays were performed before and after completion of chemotherapy.

Results

Sixty-five patients were included in study. NSE levels were significantly higher in patients who died of SCLC. The pre-treatment NSE levels in patients who responded to treatment were significantly lower. The post-treatment NSE levels were not significantly correlated with response to chemotherapy, progression-free survival, overall survival, and prognosis of patients. Change in the NSE level between the pre- and post-treatment periods was not significantly correlated with response to treatment, progression-free survival, and overall survival.

Conclusions

NSE levels might not be related with the stage of the disease. However, a low pre-treatment NSE level might be used in predicting good response to chemotherapy in patients with SCLC. The post-treatment serum NSE levels and the rate of change between pre- and post-treatment serum levels of NSE were not related with response to chemotherapy, progression-free survival, and overall survival.

Keywords:
Small-cell carcinoma
Neuron-specific enolase
Chemotherapy
Response to treatment
Survival
Progression
Resumen
Fundamento

La enolasa específica de neurona (EEN) es el marcador tumoral más sensible para el carcinoma de pulmón microcítico en el momento del diagnóstico. El objetivo del presente estudio fue revisar la utilidad de sus valores séricos como factor pronóstico en pacientes con este cáncer y determinar la correlación entre los valores y el estadio de la enfermedad y la respuesta a la quimioterapia.

Métodos

En este estudio prospectivo, se evaluaron pacientes con carcinoma de pulmón microcítico para su respuesta a la quimioterapia, supervivencia sin progresión de la enfermedad y supervivencia global. El criterio de valoración se designó como la muerte del paciente debida a la enfermedad. Los análisis de EEN se efectuaron antes y después de completar la quimioterapia.

Resultados

Se incluyeron en el estudio 65 pacientes. Los niveles de EEN fueron significativamente más altos en los pacientes que fallecieron de la enfermedad. En pacientes que respondieron al tratamiento los valores pretratamiento fueron significativamente más bajos. Los valores postratamiento no se correlacionaron significativamente con la respuesta a la quimioterapia, supervivencia libre de progresión, supervivencia global y pronóstico de los pacientes. El cambio de los valores de EEN entre el intervalo pre y postratamiento no se correlacionó significativamente con la respuesta al tratamiento, supervivencia libre de progresión y supervivencia global.

Conclusiones

Es posible que los valores de EEN no guarden relación con el estadio de la enfermedad. No obstante, en pacientes con carcinoma de pulmón microcítico, en la predicción de una respuesta apropiada a la quimioterapia pueden usarse unos valores bajos previos al tratamiento. Los valores séricos postratamiento y la tasa del cambio entre los valores pre y postratamiento no se relacionaron con la respuesta a la quimioterapia, supervivencia libre de progresión y supervivencia global.

Palabras clave:
Carcinoma de pulmón microcítico
Enolasa específica de neurona
Quimioterapia
Respuesta al tratamiento
Supervivencia
Progresión
Full text is only aviable in PDF
References
[1.]
R.S. Fraser, N.L. Müller, N. Colman, P.D. Pare.
Pulmonary carcinoma.
4th ed., pp. 1070-1228
[2.]
U. Lassen, K. Osterlind, M. Hansen, P. Dombernowsky, B. Bergman, H.H. Hansen.
Longterm survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18/years. An analysis of 1,714 consecutive patients.
J Clin Oncol, 13 (1995), pp. 1215-1220
[3.]
R.M. Bremnes, S. Sundstrom, U. Aasebø, S. Kaasa, R. Hatlevoll, S. Aamdal.
Norweigian Lung Cancer Study Group: The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up.
Lung Cancer, 39 (2003), pp. 303-313
[4.]
J.E. Lima, O.M. Takayanagui, L.V. Garcia, J.P. Leite.
Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders.
Braz J Med Biol Res, 37 (2004), pp. 19-26
[5.]
K. Fizazi, I. Cojean, J.P. Pignon, O. Rixe, M. Gatineau, S. Hadef, et al.
Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy an early predictor of complete response and survival in patients with small cell lung carcinoma.
Cancer, 82 (1998), pp. 1049-1055
[6.]
N. Van Zandwijk, E. Jassem, J.M. Bonfrer, W.J. Mooi, H. van Tinteren.
Serum neuronspecific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
Semin Oncol, 19 (1992), pp. 37-43
[7.]
G.M. Oremek, H. Sauer-Eppel, T.H. Bruzdziak.
Value of tumour and inflammatory markers in lung cancer.
Anticancer Res, 27 (2007), pp. 1911-1915
[8.]
The Eastern Cooperative Oncology Group Available from: http://www.ecog.org/general/perf_stat.html.
[9.]
K. Palka, D.H. Johnson.
Small cell lung cancer: Diagnosis, treatment and natural history.
4th ed., pp. 1899-1917
[10.]
World Health Organization: Handbook for reporting the results of cancer treatment. Geneva; 1979.
[11.]
M. Van de Pol, A. Twijnstra, G.P. ten Velde, P.P. Menheere.
Neuron-specific enolase as a marker of brain metastasis in patients with small-cell lung carcinoma.
J Neurooncol, 19 (1994), pp. 149-154
[12.]
E. Quoix, A. Purohit, M. Faller-Beau, L. Moreau, J.P. Oster, G. Pauli.
Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in smallcell lung cancer patients treated with platinum-based chemotherapy.
Lung Cancer, 30 (2000), pp. 127-134
[13.]
E. Quoix, A. Charloux, E. Popin, G. Pauli.
Inability of serum neuron-specific enolase to predict disease extent in small cell lung cancer.
Eur J Cancer, 29A (1993), pp. 2248-2250
[14.]
J.S. Gronowitz, R. Bergström, E. Nôu, S. Påhlman, O. Brodin, S. Nilsson, et al.
Clinical and serologic markers of stage and prognosis in small cell lung cancer: a multivariate analysis.
Cancer, 66 (1990), pp. 722-732
[15.]
O.C. Burghuber, B. Worofka, G. Schernthaner, N. Vetter, M. Neumann, R. Dudczak, et al.
Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer.
Cancer, 65 (1990), pp. 1386-1390
[16.]
P.W. Johnson, S.P. Joel, S. Love, M. Butcher, M.R. Pandian, L. Squires, et al.
Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer.
Br J Cancer, 67 (1993), pp. 760-766
[17.]
L.G. Jorgensen, K. Osterlind, H.H. Hansen, E.H. Cooper.
Serum neuron specific enolase (NSE) is a determinant of response duration in small cell lung cancer (SCLC).
Br J Cancer, 66 (1992), pp. 594-598
[18.]
J.A. Bonner, J.A. Sloan, K.M. Rowland, G.G. Klee, J.W. Kugler, J.A. Mailliard, et al.
Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
Clin Cancer Res, 6 (2000), pp. 597-601
[19.]
N. Van Zandwijk, E. Jassem, J.M. Bonfrer, H. van Tinteren.
Value of neuron specific enolase in early detection of relapse in small cell lung carcinoma.
Eur J Cancer, 26 (1990), pp. 373-376
[20.]
E. Wójcik, J.K. Kulpa, B. Sas-Korczyƒska, S. Korzeniowski, J. Jakubowicz.
ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Anticancer Res, 28 (2008), pp. 3027-3033
[21.]
M.C. Presmanes, N. Sánchez-Mora, R. García-Gómez, M.LH. Aladro, E. Álvarez-Fernández.
Prognostic value of ERBB2 amplification and protein expression in small cell lung cancer.
Arch Bronconeumol, 44 (2008), pp. 122-126
Copyright © 2010. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?